Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05588648 · ClinicalTrials.gov registry record · Phase 1
Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma
A Phase 1 study of Osteosarcoma, sponsored by MedPacto.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 3
- Study locations
NCT05588648 is a Phase 1 study of Osteosarcoma that is actively recruiting participants, run by MedPacto. The registered enrollment target is 48 participants, below the 301-participant average among 46 other Osteosarcoma trials with a reported enrollment target (84% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT05588648, a Phase 1 study of Osteosarcoma, is actively recruiting participants, sponsored by MedPacto.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 3
- Study locations
Study Summary
MP-VAC-209 is a Phase I/II, open label, single arm, multi-center study to assess safety, tolerability, and antitumor activity of vactosertib as a single agent in adolescents and adults with recurrent, refractory, or progressive osteosarcoma. Vactosertib is given orally, twice a day, to people 12 years of age and older who meet the criteria for study enrollment.
Conditions Studied
Interventions
- DRUG Vactosertib
Study Locations (3)
Other
- National Cancer Center - Gyeonggi-do
- Korea Institute of Radiological & Medical Sciences - Seoul
Ohio
- UH Rainbow Babies & Children's Hospital - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2023-05-01 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05588648
The ClinicalTrials.gov registry entry for NCT05588648 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 301-participant average among 46 other Osteosarcoma trials with a reported enrollment target (84% lower). The listed sponsor is MedPacto, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Osteosarcoma appearing as the primary indexed condition, and to 1 intervention - of which Vactosertib is the first listed.
NCT05588648 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Other, Ohio.
Frequently Asked Questions
What is clinical trial NCT05588648 about?
NCT05588648 is a clinical study titled "Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma". MP-VAC-209 is a Phase I/II, open label, single arm, multi-center study to assess safety, tolerability, and antitumor activity of vactosertib as a single agent in adolescents and adults with recurrent, refractory, or progressive osteosarcoma. Vactosertib is given orally, twice a day, to people 12 yea...
What is the current status of trial NCT05588648?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2023-05-01. Estimated completion is 2025-12.
What conditions does trial NCT05588648 study?
This clinical trial studies the following conditions: Osteosarcoma.
What interventions are being tested in trial NCT05588648?
The interventions under investigation include: Vactosertib (DRUG).
Who is sponsoring clinical trial NCT05588648?
This trial is sponsored by MedPacto, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05588648 being conducted?
This trial has 3 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Losartan + Sunitinib in Treatment of Osteosarcoma
RECRUITING · Phase 1
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.